Navigation Links
MINRAD International, Inc. Announces Termination of RxElite Holdings Inc. as Anesthetics Distributor for the Human Market in United States
Date:11/25/2008

ORCHARD PARK, N.Y., Nov. 25 /PRNewswire-FirstCall/ -- MINRAD International, Inc. (Amex: BUF) today announced that it has terminated its Distribution Agreement for anesthetics for the human market in the United States with RxElite Holdings, Inc.(RxElite), a wholly-owned subsidiary of RxElite Inc.(OTC Bulletin Board: RXEI) effective November 21, 2008. This action was taken as a result of RxElite's failure to provide payment in full for $5.6 million plus interest in overdue accounts owed to MINRAD International, Inc. (Minrad). RxElite is required by the terms of the Distribution Agreement to immediately terminate all use of the Minrad name or mark. Minrad notified the Food & Drug Administration (FDA) on November 21, 2008 of this event to ensure Minrad is in compliance with applicable FDA regulations that apply to the discontinuance of RxElite as the commercial distributor of drugs manufactured by Minrad.

Dave DiGiacinto, President & Chief Operating Officer, commented, "we have had ongoing dialogue for several months with RxElite's senior management in attempt to work out an acceptable payment plan to collect past due amounts of $5.6 million plus interest owed to Minrad. We discussed our objective was to work out a payment plan with RxElite for all amounts owed as of June 30, 2008. In our second quarter 2008 earnings conference call on August 14, 2008, I mentioned that 'we were being proactive to improve the growth and continuity of the business.' Unfortunately we were unsuccessful in this effort, and failed to find alternative ways to work together in the U.S. Marketplace. Consequently, we had no choice but to take this action to protect our business, vendor relationships, and our shareholders who have been severely damaged by RxElite's failure to pay the amounts owed to Minrad in full. We have talked to our General Counsel about pursuing the necessary legal steps to best achieve the fullest in financial remedies."

DiGiacinto continued, "As I stated in our recent third quarter 2008 earnings release issued on November 14, 2008, we are still determined to take the necessary actions to continue to grow our U.S. anesthetic presence and management is evaluating alternative strategies to do so with our external advisor."

    Contact:    David DiGiacinto, President & Chief Operating Officer
                ddigiacinto@minrad.com
                (716) 855-1068
                www.minrad.com

About the Company

MINRAD International, Inc. is an interventional pain management company with real-time image guidance, anesthesia and analgesia, conscious sedation product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International Inc. also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company's website, www.minrad.com.

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, MINRAD International Inc.'s limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of MINRAD International Inc.'s Form 10-KSB/A, filed with the Securities and Exchange Commission on April 21, 2008. Although MINRAD International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.


'/>"/>
SOURCE MINRAD International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP
2. MINRAD International, Inc. Announces the Start of the MINRAD International Distributor Meeting in Cape Town, South Africa
3. MINRAD International, Inc. to Discuss 2007 Fourth Quarter and Full Year Financial Results on Monday, March 31, 2008
4. MINRAD International, Inc. Announces 2007 Financial Results
5. MINRAD International, Inc. Announces FDA Approval of Petrem(TM) Sevoflurane
6. MINRAD International, Inc. to Discuss 2008 Second Quarter Financial Results on Thursday, August 14, 2008
7. MINRAD International, Inc. Announces Change in Distribution Agreement with RxElite Holdings, Inc.
8. MINRAD International, Inc. to Discuss Current Business Conditions on Tuesday, November 25, 2008
9. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
10. Arrow International, Inc. Invites You to Join Its 2007 Annual Meeting of Shareholders on the Web
11. Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... , ... Health and wellness is a topic that should concern all Americans; ... experiencing an illness. Migraines are a severe form of a headache and often are ... wish the pain on their worst enemy, the feeling can last for many hours ...
(Date:2/5/2016)... NJ (PRWEB) , ... February 05, 2016 , ... ... Primary Care for Patients with Rare Diseases, a continuing medical education (CME) event ... is the first of its kind—and a first for ACCORD, whose mission is ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( ... Career Development event in New York City on Thursday, January 21, 2016. ... of Mediacom, (both alumnus of the varsity Columbia soccer program) spoke at the ...
(Date:2/5/2016)... ... , ... Susan Polk Health Insurance Company recently released a report ... in 2016. To view the report, see below, or visit Susan Polk's blog. ... Obispo seniors who rely on Medicare health insurance and whose monthly income includes social ...
(Date:2/4/2016)... ... February 04, 2016 , ... Dr. Carol Francis ... on February 19-21, 2016, in Southern California . The International Hypnosis Federation 2016 ... 30 professional speakers, including Clinical Psychologist and Hypnotherapist Dr. Carol Francis ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... -- France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for ... by age and sex in these markets. GD epidemiology report is written ... high quality, transparent and market-driven, providing expert analysis of disease trends in ... , Italy , Spain , ...
(Date:2/4/2016)... -- The Senior Care Pharmacy Coalition (SCPC) today commended ... Jason Chaffetz (R-UT) and Ranking Member Elijah ... "Developments in the Prescription Drug Market," to examine ... abusive pharmacy benefit manager (PBM) pricing practices. ... Elijah Cummings (D-MD) are diligent, serious lawmakers committed ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
Breaking Medicine Technology: